These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 20206950)

  • 1. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
    Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Paolicchi A; Franceschini SS; Salvi M; Ferrannini E
    Metabolism; 2011 Feb; 60(2):277-83. PubMed ID: 20206950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Santini E; Franceschini SS; Ferrannini E
    J Clin Endocrinol Metab; 2009 May; 94(5):1803-9. PubMed ID: 19276231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes.
    Crescioli C; Cosmi L; Borgogni E; Santarlasci V; Gelmini S; Sottili M; Sarchielli E; Mazzinghi B; Francalanci M; Pezzatini A; Perigli G; Vannelli GB; Annunziato F; Serio M
    J Endocrinol; 2007 Oct; 195(1):145-55. PubMed ID: 17911406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.
    Antonelli A; Ferrari SM; Frascerra S; Ruffilli I; Pupilli C; Bernini G; Sellari-Franceschini S; Gelmini S; Ferrannini E; Fallahi P
    J Endocrinol; 2012 May; 213(2):183-91. PubMed ID: 22378921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease.
    Antonelli A; Ferrari SM; Frascerra S; Corrado A; Pupilli C; Bernini G; Benvenga S; Ferrannini E; Fallahi P
    Exp Cell Res; 2011 Jul; 317(11):1527-33. PubMed ID: 21565188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    Antonelli A; Rotondi M; Ferrari SM; Fallahi P; Romagnani P; Franceschini SS; Serio M; Ferrannini E
    J Clin Endocrinol Metab; 2006 Feb; 91(2):614-20. PubMed ID: 16303841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Piaggi S; Gelmini S; Lupi C; Minuto M; Berti P; Benvenga S; Basolo F; Orlando C; Miccoli P
    Endocr Relat Cancer; 2009 Dec; 16(4):1299-311. PubMed ID: 19755523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer.
    Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Di Domenicantonio A; Galleri D; Santarpia L; Basolo F; Ferrannini E; Miccoli P
    Cytokine; 2012 Aug; 59(2):218-22. PubMed ID: 22633083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    Antonelli A; Ferrari SM; Fallahi P; Ghiri E; Crescioli C; Romagnani P; Vitti P; Serio M; Ferrannini E
    Cytokine; 2010 Jun; 50(3):260-7. PubMed ID: 20299237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy.
    Ferrari SM; Ragusa F; Paparo SR; Nasini F; Nardi M; Franceschini SS; Fallahi P; Antonelli A
    Autoimmun Rev; 2019 Jul; 18(7):673-678. PubMed ID: 31059842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes.
    Antonelli A; Ferrari SM; Frascerra S; Ruffilli I; Gelmini S; Minuto M; Pupilli C; Miccoli P; Sellari-Franceschini S; Ferrannini E; Fallahi P
    Mol Cell Endocrinol; 2012 Feb; 349(2):255-61. PubMed ID: 22101320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of CXCL10 secretion by interferon-γ and tumour necrosis factor-α and its inhibition by peroxisome proliferator-activated receptor-γ agonists in cultured scleroderma fibroblasts.
    Antonelli A; Ferri C; Ferrari SM; Colaci M; Giuggioli D; Fallahi P
    Br J Dermatol; 2010 Sep; 163(3):650-1. PubMed ID: 20456349
    [No Abstract]   [Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells.
    Ohama Y; Harada T; Iwabe T; Taniguchi F; Takenaka Y; Terakawa N
    Fertil Steril; 2008 Feb; 89(2):311-7. PubMed ID: 17555752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive nuclear factor kappaB activity is required to elicit interferon-gamma-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines.
    Hiroi M; Ohmori Y
    Biochem J; 2003 Dec; 376(Pt 2):393-402. PubMed ID: 12946268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl peroxide-induced TNF-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes.
    Liu J; Xia Q; Zhang Q; Li H; Zhang J; Li A; Xiu R
    Shock; 2009 Sep; 32(3):317-24. PubMed ID: 19174742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
    Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
    Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-gamma agonists attenuate angiotensin II-induced collagen type I expression in adventitial fibroblasts.
    Zhang J; Fang NY; Gao PJ; Wu LY; Han WQ; Guo SJ; Shen WL; Zhu DL
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):72-7. PubMed ID: 18047631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of PPARalpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes.
    Murakami K; Bujo H; Unoki H; Saito Y
    Eur J Pharmacol; 2007 Apr; 561(1-3):206-13. PubMed ID: 17320860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2.
    Antonelli A; Fallahi P; Ferrari SM; Giuggioli D; Colaci M; Di Domenicantonio A; Ferri C
    J Rheumatol; 2012 May; 39(5):979-85. PubMed ID: 22422499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity.
    Keslacy S; Tliba O; Baidouri H; Amrani Y
    Mol Pharmacol; 2007 Feb; 71(2):609-18. PubMed ID: 17108260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.